pharma QA – Page 72 – Pharma.Tips

Design Space Missing for modified release platforms: decision tree for lab vs manufacturing root cause

Identifying the Absence of Design Space in Modified Release Platforms: A Methodical Investigation Approach In the pharmaceutical manufacturing landscape, identifying a missing design space for modified release platforms can often…

Specification Justification Gap for modified release platforms: risk assessment and validation impact analysis

Addressing Specification Justification Gaps in Modified Release Platforms: An Investigative Approach In the complex world of pharmaceutical manufacturing, addressing specification justification gaps, particularly for modified release platforms, can pose significant…

Control Strategy Weakness for long-acting injectables: regulatory-ready investigation and CAPA plan

Investigation into Control Strategy Weaknesses for Long-Acting Injectables: A Regulatory-Ready Approach In the landscape of pharmaceutical manufacturing, control strategy weaknesses can disrupt the quality and efficacy of long-acting injectables, potentially…

API melting point / DSC anomaly during EU GMP inspection preparation: control strategy updates for CPPs/CMAs and continued process verification

Identifying and Addressing API Melting Point DSC Anomalies in EU GMP Inspection Preparation Pharmaceutical manufacturing is susceptible to various anomalies that can affect product quality. One such issue is the…

Ph Drift during method transfer: manufacturing vs lab root cause decision tree

Understanding pH Drift During Method Transfer: A Root Cause Investigation Framework In pharmaceutical manufacturing, one critical issue that can arise during method transfer is pH drift. This phenomenon can lead…

Crimp Diameter Variability at stability pull: FDA/MHRA inspection-ready documentation

Understanding Crimp Diameter Variability During Stability Pulls: An Investigation Framework Crimp diameter variability during stability pulls can pose significant challenges in pharmaceutical manufacturing, particularly for aerosol formulations. Variability in crimp…

Spray Pattern Failure in MDI assembly: FDA/MHRA inspection-ready documentation

Addressing Spray Pattern Failures in MDI Assembly: An Investigation Framework Within the pharmaceutical manufacturing landscape, especially in the realm of metered-dose inhalers (MDIs), ensuring consistent spray patterns is crucial for…

API photostability failure after equipment maintenance intervention: control strategy updates for CPPs/CMAs and continued process verification

Control Strategy Updates Following API Photostability Failure After Equipment Maintenance Intervention In the pharmaceutical manufacturing landscape, maintaining strict compliance with Good Manufacturing Practices (GMP) is essential for ensuring product quality…

Tag: pharma QA

Design Space Missing for modified release platforms: decision tree for lab vs manufacturing root cause

Specification Justification Gap for modified release platforms: risk assessment and validation impact analysis

Control Strategy Weakness for long-acting injectables: regulatory-ready investigation and CAPA plan

API melting point / DSC anomaly during EU GMP inspection preparation: control strategy updates for CPPs/CMAs and continued process verification

Ph Drift during method transfer: manufacturing vs lab root cause decision tree

Crimp Diameter Variability at stability pull: FDA/MHRA inspection-ready documentation

Spray Pattern Failure in MDI assembly: FDA/MHRA inspection-ready documentation

API photostability failure after equipment maintenance intervention: control strategy updates for CPPs/CMAs and continued process verification

Microbial Limits Failure during line setup: GMP documentation for FDA/EMA/MHRA review

Pressure Loss during line setup: packaging integrity and transport risk assessment

E&L Failure in MDI assembly: method variability vs true product failure assessment

Net Content Failure during inspection readiness: packaging integrity and transport risk assessment